Heart disease became the leading cause of death among Hispanic adults in the U.S. in 2022, and a new American Heart Association statement says risk varies by heritage, with gaps in coverage, language and food access adding to the burden.
|Articles|December 1, 2002
Aetna rethinks its pharmacy strategy, brings business in-house
National Reports- The escalating cost of pharmacy benefits gainedattention when Aetna announced that it would keep its pharmacy operationin-house and terminate its outside mail-order contract with Express Scripts.
Advertisement
Advertisement
Related to this article
A five-session course of transcranial magnetic stimulation (TMS) improved processing speed in people with schizophrenia, a cognitive domain that is among the most severely affected in patients,
National Alliance names Jenny Goins interim CEO after former leader’s arrest; details emerge on charges, firing timeline, and impact on healthcare policy circles.
Only 19% use AI predictive models in cancer care despite strong belief in impact; 2026 Oncology Care Index highlights reimbursement, training, funding barriers.
Hispanic HIV incidence rose 16.8% in antisanctuary counties after the 2018 public charge announcement, relative to baseline counties, a new study found.
A review of randomized clinical trials, nonrandomized trials and case reports suggests that the inflammatory bowel disease risk from treatment with IL-17 inhibitors is low.
From a 95% remission rate in Japan to $81.6 billion in U.S. savings since 2015 — a data-driven look at where biosimilars stand today, and where the gaps remain.
AI pathology tool measures lung cancer treatment response after neoadjuvant chemoimmunotherapy with 91% accuracy, speeding NSCLC care while needing review for complete response.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Biosimilars are reshaping pricing and drug development — the numbers behind it
2
National Alliance names interim head after arrest of its president
3
Community oncologists are turning to AI, but not all of them use predictive models
4
The IBD risk among patients with hidrandentitis suppurtiva treated with IL-17 inhibitors: Low but not nothing
5